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ABSTRACT Hyperglycaemia is common in patients with community-acquired pneumonia (CAP) and is
a predictor of severe outcomes. Data are scarce regarding whether this association is affected by diabetes
mellitus (DM) and also regarding its importance for severe outcomes in hospital. We determined the
impact of blood glucose on severe outcomes of CAP in hospital.
We studied 1318 adult CAP patients hospitalised at three Danish hospitals. The association between
blood glucose and DM status and severe clinical outcome (admission to an intensive care unit (ICU) and/
or in-hospital mortality) was assessed by logistic regression. Models were adjusted for CURB-65 score and
comorbidities.
12% of patients had DM. In patients without DM an increase in admission blood glucose was associated
with risk for ICU admittance (OR 1.25, 95% CI 1.13–1.39), but not significantly associated with in-
hospital mortality (OR 1.10, 95% CI 0.99–1.23). In patients with DM an increase in admission blood
glucose was not associated with ICU admittance (OR 1.05, 95% CI 1.00–1.12) or in-hospital mortality (OR
1.05, 95% CI 0.99–1.12).
An increase in admission blood glucose (only in patients without DM) was associated with a higher risk
for ICU admittance and a trend towards higher in-hospital mortality. DM was not associated with a more
severe outcome of CAP.
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ORIGINAL ARTICLE
PNEUMONIA
Introduction
Hyperglycaemia is frequent at admission in patients with and without diabetes mellitus (DM) [1]. It may
be secondary to DM (diagnosed or undiagnosed) or stress. Stress-induced hyperglycaemia is a result of an
increase in catecholamines, glucagon, growth hormone, proinflammatory cytokines and increased
peripheral insulin resistance in response to physiological stress [2]. Systemic bacterial and viral infections
are potent triggers of stress hyperglycaemia and this may also be the case for pneumonia.
Community-acquired pneumonia (CAP) remains a leading cause of hospitalisation and mortality
worldwide [3, 4]. The incidence of hospitalisations caused by pneumonia has increased steadily
worldwide [5]. Rates in Denmark have increased from 288 to 809 per 100000 person-years over recent
decades [6]. Previous studies have suggested that hyperglycaemia may be associated with severe outcome in
a range of conditions, including sepsis [1, 7, 8]. In some CAP studies, an association with higher mortality
has also been reported [9–12], while others have shown no association [13, 14]. Most studies have focused
on the association between hyperglycaemia and long-term mortality (28–90 day mortality) after an episode
of CAP [10, 13]. Thus, there is a need for further analysis on the impact of hyperglycaemia on morbidity
and mortality associated with CAP, and particularly in-hospital mortality.
The main objective of the present study was to determine the impact of blood glucose levels on severe
outcomes of CAP, defined as admission to an intensive care unit (ICU) and in-hospital mortality.
Secondarily, we aimed to determine the impact of blood glucose levels on the clinical course of CAP.
Methods
Study population
We retrospectively included adult patients admitted to three Danish hospitals (one teaching and two smaller
referral hospitals) in the CAP-NORTH cohort. This cohort has been described in detail elsewhere [15].
In brief, data were collected between January 1, 2011 and June 30, 2012. The hospitals served a population of
approximately 360000 citizens. The hospitals received all patients in need of acute hospital admittance
because of the free access to treatment in public hospitals and absence of private medical emergency hospitals.
Thus the study covered all patients residing in the catchment area of these hospitals. Patients admitted with
pneumonia were identified based on the International Classification of Diseases 10th revision (ICD-10) codes
noted at discharge. All patients who had one of the following ICD-10 codes either as primary or secondary
diagnosis were evaluated for inclusion: pneumonia J10.0, J11.0 and J12.x–J18.x, J69.x, Mycoplasma
pneumoniae B96.0, Klebsiella pneumoniae B96.1, Ornithosis A70.x and Legionellosis A481.
Patient files were reviewed to assess whether the study inclusion and exclusion criteria were fulfilled (table 1).
In brief, CAP was considered in patients with symptoms of lower respiratory tract infection, a new infiltrate
on chest radiography and no hospital admission within the last 28 days. Each patient could only be included
once into the study and was registered at their first presentation with CAP [15]. Information on DM was
retrieved from the patient files and the patients were categorised as DM if 1) DM was self-reported, 2) the
attending physician stated that the patient had DM or 3) the patient received either oral or injectable
anti-diabetes medication before admission.
Data collection
Baseline characteristics, comorbidity and clinical findings at admission were collected from patient files.
Data were entered into the CAPNETZ database (www.capnetz.de) as well as into EpiData Entry 3.1 (www.
epidata.dk). Data related to hospitalisation were collected, including the use of antibiotics, microbiological
findings and length of hospital stay (LOS). Duration of antibiotic therapy included hospitalisation and
discharge.
TABLE 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ⩾18 years
New infiltrate on chest radiography (confirmed
by radiologist)
At least one of the following symptoms of lower
respiratory tract infection
Cough
Purulent expectoration
Fever ⩾38.3 °C (rectal) or ⩾37.8 °C (ear)
Pathological lung auscultation
Hospital admission within the last 28 days prior to admission due to pneumonia
Active tuberculosis
Missing information on prior medical history
Immunosuppression, defined as
Treatment with corticosteroids (⩾20 mg prednisolone-equivalent/day >14 days)
HIV infection
Received cancer chemotherapy within the last 28 days and had neutropenia
(neutrophil granulocytes <1000 µL−1)
Immunosuppression after organ or bone marrow transplantation
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Treatment length was registered as total length of antibiotic treatment (LOAB) and length of intravenous
antibiotic treatment (LOIVAB). LOAB, LOIVAB and LOS were used as markers of the clinical course of
CAP. As markers of severe outcome of CAP we considered admittance to intensive care unit (ICU) and/or
death in hospital. Admission glucose was defined as the first measured glucose value on the admission
day. We used CURB-65 as a severity score [16].
Except for comorbidities, data not mentioned/recorded in patients’ files were noted as missing.
Ethics
The study was approved by the Danish Health and Medicines Authority (3-3013-340/1/) and the Danish
Data Protection Agency (HIH-2013-017). Informed consent is not required under Danish legislation for
register-based studies.
Statistics
Data were analysed using SAS Enterprise Guide version 5.1 (SAS Institute A/S). Data were described as
counts (%) for categorical variables and either means (standard deviation (SD)) or medians (interquartile
range (IQR)) for continuous variables as appropriate. The t-test, Wilcoxon rank sum test, χ2 and Fisher’s
exact test were used to test for differences between participants with and without DM, as appropriate.
Where relevant, we adjusted for multiple comparisons using the Bonferroni correction. Patients who died
in hospital were reported as having missing LOS.
Due to the skewed distribution, the clinical course outcome variables (LOIVAB, LOS and LOAB) were
log-transformed (ln) and the proposed predictors, blood glucose levels and DM (DM versus non-DM)
TABLE 2 Characteristics of patients with and without diabetes mellitus at time of admission
Diabetes Nondiabetes p-value
Patients 12.3 (162) 87.7 (1156)
Demographic data
Age years 73 (65–80) 71 (58–82) 0.06
Male 64.2 (104) 45.1 (521) 0.001
Current smoker 23.8 (35) 27.9 (295) 0.30
Nursing home resident 8.6 (14) 11.4 (131) 0.30
Comorbidities
Obstructive pulmonary disease 23.6 (38) 17.9 (205) 0.08
Other pulmonary disease 11.8 (19) 11.7 (135) 0.98
Heart failure 16.7 (27) 7.4 (86) <0.001
Other cardiac disease 27.2 (44) 14.1 (163) <0.001
Liver disease 0.62 (1) 0.95 (11) 1.0
Kidney disease 8.6 (14) 2.3 (27) <0.001
Cerebrovascular disease 13.0 (21) 9.9 (114) 0.22
Other neurological disease 1.9 (3) 4.3 (50) 0.13
Malignancy 7.4 (12) 9.3 (107) 0.44
Admission blood glucose# mM 9.2 (7.3–13.5) 6.8 (6.0–7.9) <0.001
Blood glucose ⩽6 mM 8.8 (14) 28.0 (317) <0.001+
Blood glucose 6.1–11 mM 52.8 (84) 68.8 (780) <0.001+
Blood glucose ⩾11.1 mM 38.4 (61) 3.2 (36) <0.001+
CURB-65
0–1 36.7 (51) 55.5 (553) <0.001+
2 42.5 (59) 27.2 (271) <0.001+
3–5 20.9 (29) 17.4 (173) 0.93+
CURB-65 parameters
Confusion 13.1 (21) 14.4 (162) 0.68
Urea >7.0 mM 57.2 (91) 37.2 (424) <0.001
Respiratory rate ⩾30 min−1 16.3 (22) 10.9 (112) 0.11
Blood pressure¶ 15.7 (25) 15.3 (172) 0.89
Age ⩾65 years 77.2 (125) 56.2 (741) 0.001
Data are presented as % (n) or median (interquartile range). All variables had <3% missing data except for
current smokers (n=113, 8.5%) and CURB-65 (n=182, 13.8%). #: range 1.3–73.1 mM in diabetes patients
and 3.2–21.2 mM in nondiabetes patients; ¶: systolic <90 and/or diastolic ⩽60 mmHg; +: Bonferroni
adjusted.
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were assessed using a linear regression model. The association was assessed in univariate analyses and in a
multivariate model to adjust for possible confounders. The regression coefficients were back-transformed
(100%×(ecoefficient−1), 95% CI 100%×(eupper limit−1)–100%×(elower limit−1)) to provide percentage effects.
We used logistic regression analyses to assess the risk of severe outcome, which was defined as ICU
admittance, in-hospital mortality or combined risk (ICU admittance and/or in-hospital mortality).
Admittance blood glucose (continuous variable) was used to predict severe outcome and, because the
impact of blood glucose levels may be affected by diabetes status, we tested for an interaction between
blood glucose level and diabetes status. To adjust for confounding, relevant predictors (CURB-65, chronic
obstructive pulmonary disease (COPD), heart diseases and chronic kidney disease) were adjusted for.
Additionally, we assessed the association between pre-admission diabetes status (categorical variable) on
the risk of a severe outcome in a similar model, unadjusted and adjusted. All statistical comparisons were
two-sided and carried out at the 0.05 significance level.
Results
The CAP-NORTH cohort comprised 1320 patients with CAP [15], and data for 1318 patients were
available for this study. Two patients were not included due to missing information on prior medical
history. In total, 12.3% (162/1318) of patients were known to have DM at admittance (table 2). There were
no differences between patients with and without DM with respect to age, nursing home residency and
smoking habits, but more patients with DM were male (64.2% versus 45.1%, p=0.001) and more often had
chronic cardiac and kidney disease. Patients with DM were less likely to have received antibiotic treatment
prior to admission (29.4% versus 37.6%, p=0.04). Patients with DM had higher median admittance blood
glucose levels (9.2 mmol·L−1 versus 6.8 mmol·L−1 (mM), p<0.001). 38% and 3% (p<0.001) of patients with
and without DM had admittance blood glucose ⩾11.1 mM, respectively. At the time of admission, more
patients with DM (63.4% versus 44.6%, p<0.001) had signs of moderate to severe pneumonia according to
CURB-65 (table 2), predominantly due to age >65 years and urea >7.0 mM.
Association between admission blood glucose, DM and clinical course of CAP
We assessed whether the clinical course of CAP was different in patients with DM than in patients
without DM, and found that LOS and LOIVAB for patients with DM were longer (6 days versus 5 days,
p<0.001; 4 days versus 3 days, p=0.01) (table 3), whereas LOAB was similar in patients with and without
DM (p=0.87). In order to adjust for potential confounders (CURB-65 score and comorbidities), we
performed a linear regression analysis on log-transformed data, and found that LOS remained associated
with DM, corresponding to a 22% (95% CI 5.15–41.37%) longer admission time compared to patients
without DM. The association between DM and LOIVAB disappeared after adjusting (9%, 95% CI
−5.27–26.20%).
Subsequently, we assessed the influence of admission blood glucose in an adjusted linear regression model and
found that for each 1 mM increase in blood glucose, LOS increased by 2.8% (95% CI 0.70–4.25%) and the length
of LOIVAB was extended by 1.4% (95% CI 0.03–3.01%). Blood glucose levels did not influence the LOAB.
TABLE 3 Influence of diabetes mellitus on the clinical course of community-acquired
pneumonia
Diabetes patients Nondiabetes patients p-value#
Patients 12.3 (162) 87.7 (1156)
Clinical course days median (IQR)
LOS¶ 6 (4–10) 5 (3–8) <0.001
LOAB 10 (8–12) 10 (8–12) 0.87
LOIVAB 4 (2–7) 3 (2–6) 0.01
Severe outcome
ICU admittance 13.0 (21) 9.2 (106) 0.13
In-hospital mortality 10.5 (17) 8.1 (94) 0.31
Any severe event+ 19.8 (32) 13.9 (161) 0.05
Data are presented as % (n), unless otherwise stated. Missing information for length of antibiotic
treatment (LOAB) and intravenous antibiotic treatment (LOIVAB) were 34 (2.5%) and 12 (0.9%) patients,
respectively. IQR: interquartile range; LOS: length of stay; ICU: intensive care unit. #: LOS, use of
antibiotics, need for ICU support and mortality were assessed in a univariate analysis stratified by
diabetes; ¶: patients who died in hospital were counted as missing data (n=111, 8.4%); +: in-hospital
mortality and/or ICU admission.
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Association between admission blood glucose levels and DM status and the risk of severe
outcome
In total, 19.8% (32/162) patients with and 13.9% (161/1156) without DM had a severe outcome during
hospital admission. This included admission to an ICU (13.0% versus 9.2%) and in-hospital death (10.5%
versus 8.1%) (table 3).
The difference between patients with and without DM with regard to overall risk of severe outcome (ICU
and/or in-hospital death) was borderline significant (OR 1.52, 95% CI 0.998–2.32, p=0.051) by univariate
analysis, whereas the differences in risk of either ICU admittance or death were not significant (table 4).
By multivariate analysis adjusting for CURB-65 and comorbidity (table 4), DM was no longer associated
with any overall severe outcome (OR 1.43, 95% CI 0.88–2.31), in-hospital death (OR 0.92, 95% CI
0.47–1.79) or ICU admittance (OR 1.62, 95% CI 0.93–2.82).
We assessed the effect of blood glucose levels on severe outcome and found, in an unadjusted analysis,
that the level of admittance blood glucose was associated with any severe outcome in both patients with
and without DM. Specifically, for each 1 mM increase in glucose level, the OR for ICU admittance was
1.26 (95% CI 1.16–1.38) for patients without DM and 1.08 (95% CI 1.02–1.14) for patients with DM
(table 5). Adjustment for CURB-65 and comorbidity lowered the OR for patients with DM (OR 1.05, 95%
CI 1.00–1.12), but not for patients without DM (OR 1.25, 95% CI 1.13–1.39).
Similarly, elevated admission blood glucose was associated with increased in-hospital mortality (OR 1.24,
95% 1.13–1.35) in patients without DM, although this was partially confounded by CURB-65 and
comorbidities (adjusted OR 1.10, 95% CI 0.99–1.23). Known diabetes did not seem to be associated with
excess risk of mortality.
There was a strong interaction between DM status and blood glucose levels (test for interaction, p=0.01).
This indicated that the association between blood glucose levels and ICU admittance depends on
pre-admission DM status, and was more pronounced in patients without DM.
Discussion
We assessed the impact of blood glucose levels on severity of CAP. An increase in admission blood glucose
was associated with a more severe outcome of CAP, predominantly in patients without DM. DM was not
associated with in-hospital mortality or ICU admittance.
An increase in blood glucose at hospital admission was associated with prolonged LOS, LOIVAB and severe
outcome (ICU and in-hospital mortality). Interestingly, the association between increasing blood glucose
and LOS, LOIVAB and severe outcome was most pronounced for patients without DM. Diabetes was
associated with prolonged LOS and LOIVAB, but only LOS remained significant after adjusting for
confounders. Hyperglycaemia has been associated with excess mortality in patients admitted to ICUs [17]
and in CAP patients with hyperglycaemia [9, 10, 18], although the literature is inconsistent [13, 14]. In
2012, LEPPER et al. [10] found, in a large prospective multicentre cohort study of CAP, that hyperglycaemia is
strongly associated with 90 day mortality in patients without DM. The study by LEPPER et al. was a
prospective study, where the patients were younger and one-third were not hospitalised. Despite differences
in design and population, our study confirms this and other previous studies in showing that elevated blood
glucose in patients without DM may be associated with severe outcome and mortality [9, 10, 18].
TABLE 4 Risk of severe outcome depending on diabetes status
Crude analyses Multivariate analyses#
OR (95% CI) p-value Adjusted OR (95% CI) p-value
Any severe outcome¶
Nondiabetes patients Ref. Ref.
Diabetes patients 1.52 (0.998–2.32) 0.051 1.43 (0.88–2.32) 0.15
ICU admission
Nondiabetes patients Ref. Ref.
Diabetes patients 1.48 (0.9–2.43) 0.13 1.62 (0.93–2.82) 0.09
In-hospital mortality
Nondiabetes patients Ref. Ref.
Diabetes patients 1.33 (0.77–2.29) 0.31 0.92 (0.47–1.79) 0.80
ICU: intensive care unit. #: 1128 patients; adjusted for CURB-65, chronic obstructive pulmonary disease,
heart disease and chronic kidney disease. ¶: in-hospital mortality and/or ICU admission.
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The association between an increase in admission blood glucose and a severe clinical course was most
prominent in patients without DM. This is a somewhat counterintuitive finding, although the interaction
between blood glucose and DM has been reported previously [10, 12, 19]. Explanations for the fact that
hyperglycaemia in patients with DM apparently seemed less detrimental could be that patients with DM
were more likely to have chronically elevated blood glucose levels than patients without DM. The stress
hyperglycaemia response in patients with DM may therefore be overestimated due to higher glycaemic
baseline levels compared to patients without DM. Moreover, clinicians may have had more focus on
subsequent blood glucose regulation in patients with DM. However, it remains controversial whether tight
glucose regulation is beneficial in the acute stages of diseases [20, 21].
In this cohort of hospitalised CAP patients, 12.3% had DM, which was comparable to recent studies of
CAP, where the DM prevalence ranged from 9.8% to 21.4% [9, 10, 22, 23]. We did not find any
association between DM and an increased risk of ICU admittance or in-hospital mortality, in spite of
more severe disease at admittance based on the CURB-65 score. This is in contrast to previous studies
reporting a higher mortality of patients with CAP and DM [9, 10, 24, 25]. We found comparable
in-hospital mortality for patients with and without DM (10.5% and 8.1%, respectively) whereas LEPPER
et al. [10] reported an increased 90 day mortality (14.5% versus 6%) while FALGUERA et al. [25] reported an
increased 30 day mortality (17% versus 8%) of patients with DM compared to patients without DM.
Mortality was similar in patients with and without DM at days 30 and 90 (11% and 15%, respectively) in
our cohort [15].
The comparable mortality of patients with and without DM may be due to several factors. Firstly, all
hospitalised patients were included, regardless of severity or mental status, including patients admitted to
the ICU and those who died within the initial 24 h. These patients may be problematic to include in
prospective studies due to difficulties in obtaining informed consent and a potential source of selection
bias. Thus, patients included in our study were older and most likely more severely ill at admission, and
the impact of DM was of minor importance compared to the overall severity.
Secondly, better overall management and earlier detection of patients with DM may result in lower than
expected mortality from pneumonia. The age-standardised mortality rate among patients with DM in
Denmark has been reduced by 22%, from 1.90 in 1997 to 1.49 in 2012 [26]. In this regard it would have
been interesting to determine if differences in glycated haemoglobin (HbA1c) between the studies could
confirm the hypothesis that better regulated DM patients had lower CAP-related mortality. These facts
suggest that the excess mortality of pneumonia previously reported in diabetics is declining, while the
average mortality in pneumonia is constant [6]. This may explain why we were not able to detect a
difference in mortality between patients with and without DM.
Stress-induced hyperglycaemia is caused by a complex interplay of hormones such as catecholamines,
growth hormone, cortisol and cytokines, which leads to excessive hepatic glucose production and insulin
TABLE 5 Association between blood glucose levels and severe outcome in patients with and
without diabetes mellitus
Crude analyses Multivariate analyses#
OR (95% CI) p-value Adjusted OR (95% CI) p-value
Any severe outcome¶
Admission blood glucose per 1 mM+
Nondiabetes patients 1.31 (1.21–1.43) <0.001 1.23 (1.12–1.35) <0.001
Diabetes patients 1.06 (1.004–1.11) 0.03 1.05 (0.99–1.11) 0.09
ICU admission
Admission blood glucose per 1 mM+
Nondiabetes patients 1.26 (1.16–1.38) <0.001 1.25 (1.13–1.39) <0.001
Diabetes patients 1.08 (1.02–1.14) 0.01 1.05 (1.00–1.12) 0.07
In-hospital mortality
Admission blood glucose per 1 mM+
Nondiabetes patients 1.24 (1.13–1.35) <0.001 1.10 (0.99–1.23) 0.09
Diabetes patients 1.04 (0.99–1.09) 0.15 1.05 (0.99–1.12) 0.11
ICU: intensive care unit. #: 1116 patients; adjusted for CURB-65, chronic obstructive pulmonary disease,
heart disease and chronic kidney disease. ¶: in-hospital mortality and/or ICU admission. +: stratified for
diabetes status due to a strong interaction between diabetes status and blood glucose.
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resistance [1]. Stress hyperglycaemia is mediated by greater inflammatory and neuroendocrine alterations
than are expected in chronic hyperglycaemia, and some of these alterations might be subject for an
intervention [1]. Microvascular endothelial dysfunction, e.g. as seen in multiorgan failure, has been
associated with stress hyperglycaemia, and one study suggests that improved outcomes associated with
intensive insulin therapy may in part be to endothelial protection [1, 27]. Our study does not allow any
conclusions on the beneficial effects of glycaemic control during severe infections. Therefore, studies in a
non-ICU setting are required to determine whether optimal regulation of blood glucose levels improves (at
least in the short term) outcomes in CAP.
Limitations
Firstly, our study was retrospective and observational, and we were not able to determine any causality
between hyperglycaemia and severe outcome, and we cannot exclude that there was residual confounding
that was not accounted for. Secondly, relying on self-reported DM gives rise to the problem that a
proportion of our patients might have had unrecognised DM. Determination of HbA1c levels on
admission could have solved this problem, but this information was not available. Thirdly, we cannot
exclude that our sample was too small and hence lacked the power to detect a difference in mortality
between patients with and without DM. Fourthly, glucocorticoids may increase blood glucose levels [28].
Therapy with glucocorticoids of more than 20 mg daily for more than 14 days prior to admission was an
exclusion criterion. Glucocorticoids are not recommended for CAP in Denmark. Only patients with
suspicion of COPD exacerbations would have been offered prednisolone treatment for 10 days. We did not
register the use of glucocorticoids during admission, but we did adjust our analysis for COPD. Fifthly, we
did not register the time or nature of fluid resuscitation, which could have had an impact on blood glucose
levels, and we did not have information on time from admission to antibiotic treatment. Sixthly, although
our study in general had few missing values, nearly 14% of the patients were missing a CURB-65 score.
Finally, some patients with CAP might have been missed if they were discharged with a diagnosis other
than pneumonia.
Strengths
Due to the multicentre design, data were available for the entire geographic region and we believe that the
cohort was representative of patients hospitalised with CAP in economically developed countries.
Secondly, we evaluated both the primary and secondary diagnosis of pneumonia. This ensured that no
patients were excluded due to severe illness or atypical presentation of CAP. Thirdly, by applying our
inclusion and exclusion criteria we eliminated the potential confounding of hospital-acquired pneumonia
and excluded non-pneumonia patients. Finally, the study reflected “real life”, with no excessive focus on
study patients or adherence to specific treatment regimens. This may allow for careful generalisation of the
results.
Conclusions
An increase in admission blood glucose was an important clinical indicator of CAP severity, preferentially
among patients without DM, while DM did not affect the severity of CAP in terms of risk of ICU
admittance or in-hospital mortality. In patients without DM, an increase in blood glucose was associated
with a higher risk for ICU admittance and a tendency towards an association with in-hospital mortality in
line with recent evidence.
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